# Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial

> **NCT04602065** · PHASE1,PHASE2 · TERMINATED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 9 (actual)

## Conditions studied

- Extranodal NK/T Cell Lymphoma, Nasal Type

## Interventions

- **DRUG:** IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)

## Key facts

- **NCT ID:** NCT04602065
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-24
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-02-28
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Due to the company's development strategy adjustment, Innovent Biologics has decided not to continue this study after consultation with investigators.
- **Last updated:** 2023-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04602065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04602065, "Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04602065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*